胺碘酮通过PPARα信号通路诱导肝脏脂肪变的机制研究

肝脏 ›› 2023, Vol. 28 ›› Issue (7): 818-822.

胺碘酮通过PPARα信号通路诱导肝脏脂肪变的机制研究

孙双双, 陶帅, 汤茜茜, 傅青春

201508 上海市公共卫生临床中心肝病中心(孙双双,汤茜茜,傅青春),科研处(陶帅)

收稿日期:2023-04-30 发布日期:2023-09-19
通讯作者: 傅青春, Email :qcfu85@163.com
基金资助:
国家自然科学基金(8180030029)

Mechanism study of liver steatosis induced by amiodarone via PPARα signaling pathway

SUN Shuang-shuang¹,TAO Shuai²,TANG Xi-xi¹,FU Qing-chun¹

1. Department of Hepatology Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China;
2. Department of Scientific Research, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China

Received:2023-04-30 Published:2023-09-19
Contact: FU Qing-chun, Email:qcfu85@163.com

摘要/Abstract

摘要： 目的探讨胺碘酮诱导的肝脏脂肪变的机制。方法 8周雄性C57BL/6J小鼠分为3组,每组5只:正常饮食为空白对照组(WT组,n=5);胺碘酮(150 mg·kg^-1·d^-1)灌胃10 d为模型组(胺碘酮组,n=5);干预治疗组[胺碘酮+PPARα激动剂WY14643(2.5 mg/kg),n=5]即胺碘酮造模同时使用WY14643(2.5 mg/kg)灌胃,连续10 d。10 d后检测小鼠血清丙氨酸氨基转移酶、天冬氨酸氨基转移酶、甘油三酯、总胆固醇和高密度脂蛋白,HE染色和油红染色观察肝脏病理学改变;RT-PCR检测肝组织内过氧化物酶体增殖物激活受体α(PPARα)及其调节的脂代谢基因的表达。数据组内比较采用t检验,组间比较用单因素方差分析,半定量资料采用非参数检验的Mann-Whitney U检验。结果 WY14643干预治疗组肝组织油红及HE染色结果显示,肝内脂肪变较模型组小鼠明显减少。RT-PCR检测结果显示,胺碘酮组PPARα及下游相关基因CPTI、ACOX、Cyp4a14的mRNA表达均下降,治疗后PPARα及部分相关基因CPTI、ACO、Cyp4a14表达较胺碘酮组上升(P=0.0003,0.0157,0.0057,0.0203)。结论胺碘酮可能通过调控PPARα及其下游相关基因诱发肝脏脂肪变。

关键词: 胺碘酮, 肝脏脂肪变, 线粒体, 过氧化物酶体增殖物激活受体α

Abstract: Objective To investigate the mechanism of hepatic steatosis induced by amiodarone. Methods Male C57BL/6J mice aged 8 weeks were divided into 3 groups of 5.control group with normal diet (WT group, n=5); Amiodarone at 150mg.kg-1.d-1 was administered intragastatically for 10 days as the model group (AM group, n=5). In the intervention group (AM+PPARα agonist WY14643 (2.5mg/kg), n=5) amiodarone was used simultaneously by gavage with WY14643 (2.5mg/kg) for 10 consecutive days;After 10 day, serum alanine aminotransferase, aspartate aminotransferase, triglyceride, total cholesterol and high density lipoprotein in each group were detected.The pathological changes of liver were observed by HE staining and oil red staining. The expression of PPARαand its regulated lipid metabolism genes were detected by RT-PCR. t test was used for intra-group comparison, one-way analysis of variance was used for inter-group comparison, and Mann-Whitney U test for non-parametric test was used for semi-quantitative data. Results Pathological observation showed that compared with the model group, the results of liver oil red and HE staining in the intervention group showed that the liver fat change was significantly reduced ;RT-PCR results showed that mRNA expression of PPARαand downstream related genes CPTI, Cyp4a14, Acot1decreased in amiodarone group. After treatment, the expressions of PPARα and some related genes were increased compared with those of model group ((P=0.0003, 0.0157, 0.0057, 0.0203). Conclusion Amiodarone may induce liver steatosis by regulating PPARα and its downstream related genes.

Key words: Amiodarone, Fatty liver, Mitochondria, PPARα

孙双双, 陶帅, 汤茜茜, 傅青春. 胺碘酮通过PPARα信号通路诱导肝脏脂肪变的机制研究[J]. 肝脏, 2023, 28(7): 818-822.

SUN Shuang-shuang,TAO Shuai,TANG Xi-xi,FU Qing-chun. Mechanism study of liver steatosis induced by amiodarone via PPARα signaling pathway[J]. Chinese Hepatolgy, 2023, 28(7): 818-822.

参考文献

[1] Allard J, Bucher S, Massart J et al. Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells:proof of multiple mechanism-based toxicity. Cell Biol Toxicol, 2021, 37: 151-175.
[2] Fromenty B. Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis. Liver Res, 2019, 3:157-169.
[3] Begriche K, Massart J, Robin M, et al.Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol, 2011, 54:773-794.
[4] Pate lV, Sanyal AJ. Drug-induced steatohepatitis.Clin liver Dis, 2013, 17:533-546.
[5] Simonen P, Lehtonen J, Lampi AM, et al. Desmosterol accumulation in users of amiodarone.J Intern Med, 2018, 283: 93-101.
[6] Satapathy SK, Kuwajima V, Nadelson J, et al. Drug-induced fattyLiver disease: an overview of pathogenesis and management. Ann Hepatol, 2015, 14:789-806.
[7] Montagner A, Polizzi A, Fouché E, et al.Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.Gut, 2016, 65:1202-1214.
[8] Vitins AP, Kienhuis AS, Speksnijder EN, et al.Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models.Arch Toxicol, 2014, 88:1573-1588.
[9] Lettéron P, Sutton A, Mansouri A, et al. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology, 2003, 38:133-140.
[10] Sungl PS, Yoon SK. Amiodarone hepatotoxicity. Hepatology, 2012, 55:325-336.
[11] Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation.Biochim Biophys Acta, 2016, 1863:2422-2435.
[12] Prill S, Bavli D, Levy G, et al.Real-time monitoring of oxygen uptake in hepatic bioreactor shows CYP450-independent mitochondrial toxicity of acetaminophen and amiodarone. Arch Toxicol, 2016, 90:81-91.
[13] Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity.Pharmacol Ther, 1995, 67:141-154.
[14] Mssart J, Begriche K, Buron N, et al.Drug-induced inhibition of mitochondrial fatty acid oxidation and steatosis.Curr Pathobiol Rep, 2013, 1:147-157.
[15] Montagner A, Polizzi A, Fouché E et al. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.Gut, 2016, 65: 1202-1214.
[16] Kersten S, Stienstra R.The role and regulation of the peroxisome proliferator activated receptor alpha in human liver.Biochimie, 2017, 136:75-84.